Exact Sciences (EXAS): Exploring Valuation Following Recent Share Price Gains

Exact Sciences (EXAS) shares have climbed about 17% this month and over 33% in the past 3 months. Investors are taking note as the company's annual revenue is up 10% and net income growth has accelerated.

See our latest analysis for Exact Sciences.

After surging over 17% in the last month, Exact Sciences’ recent momentum marks a sharp contrast to its longer-term results. The company’s 1-year total shareholder return remains negative at nearly -11%, while the 3-year total shareholder return stands out at an impressive 90%. This suggests investors are responding to a renewed sense of growth potential or shifting risk perceptions, especially as the share price climbs back from previous lows.

If Exact Sciences’ rebound has you rethinking what’s possible in the healthcare sector, discovering new opportunities is easy with our curated healthcare stocks screener. See the full list for free.

With recent gains and improved growth metrics in hand, is Exact Sciences offering real value at today's prices, or have markets already accounted for the company’s revived outlook, leaving little room for further upside?

Most Popular Narrative: 9.3% Undervalued

With Exact Sciences trading at $62.74 while the most popular narrative places fair value at $69.16, there is a visible valuation gap that has investors weighing long-term profit hopes against today’s recovery rally.

*Expanding payer coverage, notably new contracts with top insurers like Humana and Centene and Medicare reimbursement for new products, and increasing government screening mandates are expected to substantially boost accessibility and recurring revenue for core products such as Cologuard and Oncodetect. These factors support sustained top-line growth.*

Read the complete narrative.

What bold expectations do analysts have in mind? There is a rare blend of optimistic growth rates, margin expansion, and a future earnings multiple that grabs attention. Want to see the numbers that anchor this bullish narrative? Catch the next move behind this projected fair value before it is priced in.

Result: Fair Value of $69.16 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing high R&D spending and growing competition in colorectal cancer screening could quickly challenge Exact Sciences' outlook if market adoption slows.

Find out about the key risks to this Exact Sciences narrative.

Build Your Own Exact Sciences Narrative

If you want to dig into the details or see things from your own perspective, you can craft your own Exact Sciences story in minutes. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Exact Sciences.

Looking for More Actionable Investment Ideas?

Stay one step ahead by tapping into fresh opportunities before the crowd notices. Use these powerful stock screeners to uncover trends and smart moves for your portfolio today.

• Capture high yields with these 21 dividend stocks with yields > 3%, showing strong income potential for investors seeking steady returns from market leaders paying over 3%.
• Spot hidden value early with these 856 undervalued stocks based on cash flows, which the market may be overlooking, giving you an edge in building value-driven positions.
• Expand with breakthrough tech using these 26 AI penny stocks, featuring companies harnessing artificial intelligence to disrupt industries and lead tomorrow’s innovative growth stories.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com